According to a recent LinkedIn post from Tubulis, Chief Business Officer Ingo Lehrke is scheduled to participate in the LSX World Congress Europe in Lisbon from March 25–26. The post notes that Lehrke will speak in the Opening Keynote Fireside Chat, reflecting on the company’s trajectory since its founding in 2019.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The LinkedIn post suggests that Tubulis intends to highlight key inflection points in its development, particularly around its efforts to advance antibody-drug conjugate (ADC) therapies. For investors, this type of high-visibility conference participation can signal an effort to strengthen business development pipelines, attract partnerships, and reinforce the company’s positioning within the competitive ADC and oncology therapeutics landscape.